Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
|Articles|February 1, 2002
Supplements and Featured Publications
- New Approaches to the Treatment of Migraine: Clinical and Economic Impact
- Volume 8
- Issue 3 Suppl
Almotriptan Versus Sumatriptan in Migraine Treatment: Direct Medical Costs of Managing Adverse Chest Symptoms
Advertisement
Articles in this issue
over 24 years ago
Participating Facultyover 24 years ago
Introductionover 24 years ago
Migraine: Diagnosis, Management, and New Treatment OptionsAdvertisement
Related to this article
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
International Panel Agrees on Framework for Tapering Psoriasis Biologics
4
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
5